Novavax Statistics

Total Valuation

Novavax has a market cap or net worth of EUR 1.40 billion. The enterprise value is 1.01 billion.

Market Cap	1.40B
Enterprise Value	1.01B

Important Dates

The last earnings date was Thursday, February 26, 2026.

Earnings Date	Feb 26, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	162.94M
Shares Outstanding	n/a
Shares Change (YoY)	+13.74%
Shares Change (QoQ)	+1.74%
Owned by Insiders (%)	0.64%
Owned by Institutions (%)	59.22%
Float	140.46M

Valuation Ratios

The trailing PE ratio is 3.74.

PE Ratio	3.74
Forward PE	n/a
PS Ratio	1.47
PB Ratio	-12.89
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 1.95, with an EV/FCF ratio of -4.73.

EV / Earnings	2.69
EV / Sales	1.04
EV / EBITDA	1.95
EV / EBIT	2.08
EV / FCF	-4.73

Financial Position

The company has a current ratio of 2.13

Current Ratio	2.13
Quick Ratio	1.83
Debt / Equity	n/a
Debt / EBITDA	0.46
Debt / FCF	-1.11
Interest Coverage	24.98

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	25.72%
Return on Invested Capital (ROIC)	n/a
Return on Capital Employed (ROCE)	78.60%
Weighted Average Cost of Capital (WACC)	n/a
Revenue Per Employee	1.28M
Profits Per Employee	500,675
Employee Count	749
Asset Turnover	0.82
Inventory Turnover	39.01

Taxes

In the past 12 months, Novavax has paid 1.59 million in taxes.

Income Tax	1.59M
Effective Tax Rate	0.42%

Stock Price Statistics

The stock price has increased by +17.01% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+17.01%
50-Day Moving Average	7.34
200-Day Moving Average	6.71
Relative Strength Index (RSI)	55.52
Average Volume (20 Days)	4,124

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	10.28

Income Statement

In the last 12 months, Novavax had revenue of EUR 956.87 million and earned 375.01 million in profits. Earnings per share was 2.19.

Revenue	956.87M
Gross Profit	619.77M
Operating Income	479.71M
Pretax Income	376.59M
Net Income	375.01M
EBITDA	503.23M
EBIT	479.71M
Earnings Per Share (EPS)	2.19

Full Income Statement

Balance Sheet

The company has 626.07 million in cash and 236.81 million in debt, giving a net cash position of 389.26 million.

Cash & Cash Equivalents	626.07M
Total Debt	236.81M
Net Cash	389.26M
Net Cash Per Share	n/a
Equity (Book Value)	-108.81M
Book Value Per Share	-0.67
Working Capital	441.46M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -208.36 million and capital expenditures -4.74 million, giving a free cash flow of -213.09 million.

Operating Cash Flow	-208.36M
Capital Expenditures	-4.74M
Free Cash Flow	-213.09M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 64.77%, with operating and profit margins of 50.13% and 39.19%.

Gross Margin	64.77%
Operating Margin	50.13%
Pretax Margin	39.36%
Profit Margin	39.19%
EBITDA Margin	52.59%
EBIT Margin	50.13%
FCF Margin	n/a

Dividends & Yields

Novavax does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-13.74%
Shareholder Yield	-13.74%
Earnings Yield	26.75%
FCF Yield	-15.20%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Novavax has an Altman Z-Score of -1.81 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-1.81
Piotroski F-Score	5